228 related articles for article (PubMed ID: 23025422)
1. Cost-effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany.
Jiang Y; Gauthier A; Annemans L; van der Linden M; Nicolas-Spony L; Bresse X
Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):645-60. PubMed ID: 23025422
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.
Jiang Y; Gauthier A; Keeping S; Carroll S
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):913-27. PubMed ID: 25189087
[TBL] [Abstract][Full Text] [Related]
3. A public health and budget impact analysis of vaccinating at-risk adults and the elderly against pneumococcal diseases in Germany.
Jiang Y; Gauthier A; Annemans L; van der Linden M; Nicolas-Spony L; Bresse X
Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):631-43. PubMed ID: 23025421
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects.
Claes C; Reinert RR; von der Schulenburg JM
Eur J Health Econ; 2009 Feb; 10(1):25-38. PubMed ID: 18379830
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.
Rozenbaum MH; Sanders EA; van Hoek AJ; Jansen AG; van der Ende A; van den Dobbelsteen G; Rodenburg GD; Hak E; Postma MJ
BMJ; 2010 Jun; 340():c2509. PubMed ID: 20519267
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians.
Dirmesropian S; Wood JG; MacIntyre CR; Beutels P; McIntyre P; Menzies R; Reyes JF; Chen C; Newall AT
Vaccine; 2017 Aug; 35(34):4307-4314. PubMed ID: 28693751
[TBL] [Abstract][Full Text] [Related]
9. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales.
Andrews NJ; Waight PA; George RC; Slack MP; Miller E
Vaccine; 2012 Nov; 30(48):6802-8. PubMed ID: 23000122
[TBL] [Abstract][Full Text] [Related]
10. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.
Isaacman DJ; Strutton DR; Kalpas EA; Horowicz-Mehler N; Stern LS; Casciano R; Ciuryla V
Clin Ther; 2008 Feb; 30(2):341-57. PubMed ID: 18343273
[TBL] [Abstract][Full Text] [Related]
11. Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain).
Navas E; Salleras L; Gisbert R; Domínguez A; Timoner E; Ibáñez D; Prat A
Vaccine; 2005 Mar; 23(17-18):2342-8. PubMed ID: 15755625
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
Cho BH; Stoecker C; Link-Gelles R; Moore MR
Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland.
Blank PR; Szucs TD
Vaccine; 2012 Jun; 30(28):4267-75. PubMed ID: 22521287
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain).
Díez-Domingo J; Ridao-López M; Gutiérrez-Gimeno MV; Puig-Barberá J; Lluch-Rodrigo JA; Pastor-Villalba E
Vaccine; 2011 Dec; 29(52):9640-8. PubMed ID: 22027484
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.
Smith KJ; Wateska AR; Nowalk MP; Raymund M; Nuorti JP; Zimmerman RK
JAMA; 2012 Feb; 307(8):804-12. PubMed ID: 22357831
[TBL] [Abstract][Full Text] [Related]
16. Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands.
Rozenbaum MH; Hak E; van der Werf TS; Postma MJ
Clin Ther; 2010 Aug; 32(8):1517-32. PubMed ID: 20728764
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of pneumococcal conjugate vaccination in Australia.
Butler JR; McIntyre P; MacIntyre CR; Gilmour R; Howarth AL; Sander B
Vaccine; 2004 Mar; 22(9-10):1138-49. PubMed ID: 15003641
[TBL] [Abstract][Full Text] [Related]
18. Estimating the cost-effectiveness of a sequential pneumococcal vaccination program for adults in Germany.
Kuchenbecker U; Chase D; Reichert A; Schiffner-Rohe J; Atwood M
PLoS One; 2018; 13(5):e0197905. PubMed ID: 29795647
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries.
Ament A; Baltussen R; Duru G; Rigaud-Bully C; de Graeve D; Ortqvist A; Jönsson B; Verhaegen J; Gaillat J; Christie P; Cifre AS; Vivas D; Loiseau C; Fedson DS
Clin Infect Dis; 2000 Aug; 31(2):444-50. PubMed ID: 10987703
[TBL] [Abstract][Full Text] [Related]
20. Economic and clinical evaluation of a catch-up dose of 13-valent pneumococcal conjugate vaccine in children already immunized with three doses of the 7-valent vaccine in Italy.
Boccalini S; Azzari C; Resti M; Valleriani C; Cortimiglia M; Tiscione E; Bechini A; Bonanni P
Vaccine; 2011 Nov; 29(51):9521-8. PubMed ID: 22008820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
